Redx Pharma Plc

Redx Pharma Plc is a AIM listed biotech company focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease. Their team of ~50 scientists are based at their labs at Alderley Park, Cheshire, the UK’s largest single site life science campus (near to Manchester). The team is made up of world class medicinal chemistry, biology and clinical…More capability with deep-rooted biotech and large pharma experience. Their lead oncology asset, RXC004, is currently in a phase 1 clinical study in patients with advanced malignancies and the company’s ROCK2 selective inhibitor, RXC007, is expected to enter the clinic in 2021.